... as pralsetinib (Gavreto) and selpercatinib (Retevmo) MET inhibitors, such as capmatinib (Tabrecta) and tepotinib (Tepmetko) HER2-directed drugs, such as ado-trastuzumab emtansine (Kadcyla), fam-trastuzumab deruxtecan-nxki (Enhertu), and zenocutuzumab-zbco (Bizengri) — which recently received accelerated approval TRK inhibitors, such as entrectinib (Rozlytrek ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... as pralsetinib (Gavreto) and selpercatinib (Retevmo) MET inhibitors, such as capmatinib (Tabrecta) and tepotinib (Tepmetko) HER2-directed drugs, such as ado-trastuzumab emtansine (Kadcyla), fam-trastuzumab deruxtecan-nxki (Enhertu), and zenocutuzumab-zbco (Bizengri) — which recently received accelerated approval TRK inhibitors, such as entrectinib (Rozlytrek ...
... Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) Sunvozertinib (Zegfrovy) ALK inhibitors Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) ROS1 inhibitors Ceritinib Crizotinib Entrectinib (Rozlytrek ...
NSCLC Targeted Therapy: 8 Facts
... Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) Sunvozertinib (Zegfrovy) ALK inhibitors Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) ROS1 inhibitors Ceritinib Crizotinib Entrectinib (Rozlytrek ...
... Other options include the TKIs entrectinib (Rozlytrek) and Taletrectinib (Ibtrozi).Therapy for NRG1 Gene FusionAbout 0.2 percent of people with NSCLC have an NRG1 gene fusion, in which the NRG1 gene is rearranged or becomes fused with another gene. NRG1 gene fusions prevent other lung cancer treatments from working as well. ...
Metastatic NSCLC: Symptoms and Treatments
... Other options include the TKIs entrectinib (Rozlytrek) and Taletrectinib (Ibtrozi).Therapy for NRG1 Gene FusionAbout 0.2 percent of people with NSCLC have an NRG1 gene fusion, in which the NRG1 gene is rearranged or becomes fused with another gene. NRG1 gene fusions prevent other lung cancer treatments from working as well. ...
... The good news is that several FDA-approved treatments now target these fusion-related biomarkers.Targeted therapies based on specific gene fusions include:ALK Fusion Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Lorlatinib (Lorbrena) ROS1 Fusion: Ceritinib Crizotinib Lorlatinib Entrectinib (Rozlytrek) Repotrectinib ...
Biomarkers for Lung Cancer: 12 Things To Know
... The good news is that several FDA-approved treatments now target these fusion-related biomarkers.Targeted therapies based on specific gene fusions include:ALK Fusion Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Lorlatinib (Lorbrena) ROS1 Fusion: Ceritinib Crizotinib Lorlatinib Entrectinib (Rozlytrek) Repotrectinib ...
... It’s usually seen in people with NSCLC who do not have EGFR, ALK, or KRAS mutations.Medications that target the ROS1 gene rearrangement include: Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) NTRK InhibitorsIn a small number of NSCLC cases, there are mutations in one of the NTRK genes that cause ...
Lung Cancer Treatment Options
... It’s usually seen in people with NSCLC who do not have EGFR, ALK, or KRAS mutations.Medications that target the ROS1 gene rearrangement include: Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) NTRK InhibitorsIn a small number of NSCLC cases, there are mutations in one of the NTRK genes that cause ...
... These drugs include: Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) Another ROS1 inhibitor, taletrectinib, is being studied in clinical trials.KRASKRAS mutations occur in up to 30 percent of NSCLC cases. One specific mutation, KRAS G12C, is found in 40 percent of those. ...
How Does Targeted Therapy for Lung Cancer Work?
... These drugs include: Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) Another ROS1 inhibitor, taletrectinib, is being studied in clinical trials.KRASKRAS mutations occur in up to 30 percent of NSCLC cases. One specific mutation, KRAS G12C, is found in 40 percent of those. ...
Join
